Company news

Processa Pharmaceuticals, Inc. news in 2025

Processa Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

December 17, 2025

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

November 5, 2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

August 6, 2025

Processa Pharmaceuticals Provides Portfolio and Business Update

July 1, 2025

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

June 17, 2025

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

June 17, 2025

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

June 13, 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 18, 2025

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

February 6, 2025

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

January 29, 2025

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

January 26, 2025

Decks in 2025